William Blair reiterated their buy rating on shares of AveXis (NASDAQ:AVXS) in a report published on Tuesday morning.

AVXS has been the subject of several other reports. Zacks Investment Research cut AveXis from a buy rating to a hold rating in a research report on Monday, October 30th. Bank of America reduced their price objective on AveXis from $115.00 to $112.00 and set a buy rating for the company in a research report on Friday, November 10th. Canaccord Genuity started coverage on AveXis in a research report on Thursday, October 26th. They issued a hold rating and a $110.00 price objective for the company. Royal Bank of Canada increased their price objective on AveXis from $92.00 to $97.00 and gave the company a sector perform rating in a research report on Friday, November 10th. Finally, BMO Capital Markets reissued an outperform rating and issued a $130.00 price objective (up from $123.00) on shares of AveXis in a research report on Thursday, October 12th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the stock. AveXis currently has a consensus rating of Buy and a consensus price target of $113.89.

AveXis (AVXS) opened at $118.53 on Tuesday. AveXis has a twelve month low of $53.94 and a twelve month high of $128.00. The company has a market capitalization of $4,513.94 and a P/E ratio of -21.28.

AveXis (NASDAQ:AVXS) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.48) by ($0.04). During the same quarter in the prior year, the business posted ($0.87) earnings per share. equities research analysts expect that AveXis will post -6.23 earnings per share for the current fiscal year.

In related news, VP Andrew F. Knudten sold 2,000 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $94.48, for a total value of $188,960.00. Following the completion of the transaction, the vice president now directly owns 7,000 shares of the company’s stock, valued at $661,360. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Brian K. Kaspar sold 15,000 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $94.73, for a total value of $1,420,950.00. Following the completion of the transaction, the insider now directly owns 1,826,502 shares of the company’s stock, valued at $173,024,534.46. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,560 shares of company stock valued at $4,152,752. 18.60% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the stock. Strs Ohio bought a new position in AveXis in the third quarter worth $116,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in AveXis by 57.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock worth $137,000 after purchasing an additional 453 shares during the period. Cubist Systematic Strategies LLC lifted its position in AveXis by 688.6% in the third quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after purchasing an additional 1,577 shares during the period. Teacher Retirement System of Texas bought a new position in AveXis in the third quarter worth $200,000. Finally, Deschutes Portfolio Strategy LLC bought a new position in AveXis in the third quarter worth $203,000. 82.77% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/avexis-avxs-receives-buy-rating-from-william-blair/1839683.html.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.